The FDA issued a fact sheet for healthcare providers on the Emergency Use Authorization for Pfizer’s Paxlovid, which indicates that the EUA has been revised to remove a previous requirement of SARS-CoV-2 viral testing. Reference Link
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Pfizer price target lowered to $44 from $49 at Barclays
- Pfizer Inc Reported Earnings. Did it Beat Estimates?
- Pfizer CEO: Our best days are still ahead of us
- Pfizer Issues Weak 2023 Guidance; Expects Significant Sales Drop
- Pfizer says incremental share repurchases ‘not high priority at this point’
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue